The cerebral proteopathies.

Proteopathy: the next therapeutic frontier?

4,4(')-Dianilino-1,1(')-binaphthyl-5,5(')-disulfonate: report on non-beta-sheet conformers of Alzheimer's peptide beta(1-40).

Challenges of targeting A beta fibrillogenesis and other protein folding disorders.

The Amyloid Hypothesis and the clearance and degradation of Alzheimer's beta-peptide.

Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites.

Similar promotion of Abeta1-42 fibrillogenesis by native apolipoprotein E epsilon3 and epsilon4 isoforms.

Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.

Emerging prospects for the disease-modifying treatment of Alzheimer's disease.

Multiple ligand binding sites on A beta(1-40) fibrils.